rac-nor laudanosine
CAS: 13074-31-2
Ref. 3D-FR27650
1kg | Descatalogado | ||
2kg | Descatalogado | ||
5kg | Descatalogado | ||
10kg | Descatalogado | ||
500g | Descatalogado |
Información del producto
- 1-[(3,4-Dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxyisoquinoline1,2,3,4-Tetrahydro-6,7-dimethoxy-1-veratrylisoquinoline (±)-N-Norlaudanosine
- (+/-)-Tetrahydropapaverine
- (±)-N-Norlaudanosine
- (±)-Norlaudanosine
- 1,2,3,4-Tetrahydropapaverine
- 1-(3,4-Dimethoxybenzyl)-6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinoline
- 1-(3,4-Dimethoxybenzyl)-6,7-Dimethoxy-1,2,3,4-Tetrahydroisoquinolinium Chloride
- 1-[(3,4-Dimethoxyphenyl)Methyl]-1,2,3,4-Tetrahydro-6,7-Dimethoxyisoquinoline
- Isoquinoline, 1,2,3,4-tetrahydro-6,7-dimethoxy-1-veratryl-
- Isoquinoline, 1-[(3,4-dimethoxyphenyl)methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-
- Ver más sinónimos
Rac-nor laudanosine is a potent dopamine receptor agonist that is used for the treatment of Parkinson's disease. It has been shown to inhibit cell growth in culture and reduce acid formation, which may be due to its ability to inhibit cyclic nucleotide phosphodiesterases. Rac-nor laudanosine also inhibits the production of dopamine from tyrosine by inhibiting the conversion of dopamine into dihydroxyphenylalanine via the enzyme tyrosine hydroxylase. The asymmetric synthesis of rac-nor laudanosine allows it to have a high yield with less reaction time and fewer steps. This drug was shown to bind in vitro to human receptors.